SUBSCRIBE
SUBSCRIBE
News   Drug Development

Antigenics Inc. (New York) Buoyed by Brain-Cancer Study

October 26, 2009 | 
1 min read

Bookmark and Share

Drug developer Antigenics Inc. said researchers at the University of California, San Francisco, reported positive results stemming from a study using its cancer therapy Oncophage to treat brain-cancer patients.

Clinical research Phase II
MORE ON THIS TOPIC
Pictured: An Eli Lilly Research Laboratories sign/
Cancer
Lilly’s Strong Phase III Survival Data for Jaypirca Clouded by Deaths
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration
Depression
Relmada Considering ‘Strategic Alternatives’ After Failure of Depression Asset
December 9, 2024
 · 
1 min read
 · 
Heather McKenzie
Collage with halftone hand, light bulb and head. Creative idea generation or brainstorm concept vector pop art retro style illustration. Design element for infographic, poster, website
Parkinson’s disease
A Month After Stunning Schizophrenia Fail, AbbVie’s Other Cerevel Asset Shines Again
December 9, 2024
 · 
1 min read
 · 
Annalee Armstrong
Merck Research Laboratories in South San Francisco, California
Lymphoma
Merck Touts 100% Complete Response Rate for Anti-ROR1 ADC as First-Line Lymphoma Treatment
December 9, 2024
 · 
2 min read
 · 
Tristan Manalac